相关实验视频

Updated: Sep 9, 2025

Author Spotlight: Optimizing iPSC Differentiation for Efficient Production to Generate Kidney Organoids

Author Spotlight: Optimizing iPSC Differentiation for Efficient Production to Generate Kidney Organoids

Published on: September 1, 2023

治疗FGF9可以减少IPSC衍生器官的非细胞

Virginie Joris¹, Anika Schumacher¹, Maria Paula Marks¹

¹Department of Cell Biology-Inspired Tissue Engineering, MERLN Institute for Technology-Inspired Regenerative Medicine, Maastricht University, Maastricht, The Netherlands.

NPJ Regenerative medicine

|August 30, 2025

概括

将FGF9添加到器官培养物中可以减少不必要的软骨形成. 这种改进提高了器官质量和成熟度,用于未来对药物毒性和病的研究.

科学领域:

干细胞生物学
复原医学
肝脏病学

背景情况:

药物毒性和病是重要的临床问题.
在体外模型对于研究药物毒性和疾病机制至关重要.
诱导多能干细胞衍生的器官具有前景,但需要优化以延长培养和提高纯度.

研究的目的:

修改现有的器官培养方案以提高其质量和适合长期研究.
研究纤维细胞生长因子9 (FGF9) 对脏器官的非脏细胞群减少的影响,特别是软骨.

主要方法:

与标准的Takasato协议相比,器官的培养采用了一种修改后的方案,该方案涉及将FGF9添加到培养基中长时间 (一周).
在FGF9治疗和对照器官中评估了状细胞标志物表达和软骨存在.
通过免疫光检测评估了结构完整性.

主要成果:

在第7+25天,FGF9治疗显著减少了脏器官的软骨形成.
在FGF9治疗的器官体中,冠状细胞标志物的表达有所减少.
器官中的关键结构没有受到FGF9治疗的影响.

结论:

通过减少软骨污染,补充FGF9可以改善器官质量.
这种提高的质量使器官的维护时间更长,成熟度更好.
优化器官更适合体内应用,并推进毒性和病模型研究.

更多相关视频

Isogenic Kidney Glomerulus Chip Engineered from Human Induced Pluripotent Stem Cells

Isogenic Kidney Glomerulus Chip Engineered from Human Induced Pluripotent Stem Cells

Published on: November 4, 2022

Isolation of Chondrocytes and Chondroprogenitors Using Fibronectin Adhesion and Migratory Assay

Isolation of Chondrocytes and Chondroprogenitors Using Fibronectin Adhesion and Migratory Assay

Published on: October 4, 2024

相关概念视频

iPS Cell Differentiation

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.